Center for Beta Cell Therapy in Diabetes and ViaCyte announce start of European clinical trial of human stem cell-derived implants in type 1 diabetes patients

Major step in the development of cell therapy for type 1 diabetes

BRUSSELS and SAN DIEGO -- The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium on translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company, today announced that a human stem cell-derived product candidate has been implanted in type 1 diabetes patients at a subtherapeutic dose.  These are the first patients in Europe to receive PEC-Direct, an encapsulated pancreatic progenitor cell product candidate designed to replace lost insulin-producing beta cells and restore blood glucose control for type 1 diabetes patients who fulfill entry criteria for a beta cell replacement therapy.

Potential cure for type 1 diabetes patients

In preclinical models, implants of PEC-Direct (also known as VC-02) are capable of forming a functional beta cell mass that controls blood glucose levels. This potential is now being examined in the first European clinical trial with type 1 diabetes patients who have lost blood glucose control due to beta cell loss in the pancreas. For this patient population, a beta cell replacement therapy, like PEC-Direct, can potentially provide a functional cure.

This work complements clinical evaluation of PEC-Direct that is underway in North America.  During the first phase of the European trial, implants are investigated for their ability to form beta cells; the second phase will examine their capacity to produce systemic levels of insulin that establish glucose control. The implantation in these first European patients is a major step in the development of a cell therapy for type 1 diabetes.

The implantations were performed at UZ Brussel, the University Hospital of Vrije Universiteit Brussel (VUB) with the PEC-Direct product candidate from ViaCyte. The clinical trial, and associated preclinical studies in Europe, are undertaken by the Beta Cell Therapy Consortium, with support of a Horizon 2020 grant from the European Commission. The consortium is composed of clinical, industrial, and research teams at VUB, ViaCyte, San Raffaele Hospital Diabetes Research Institute in Milan, Nestlé Institute of Health Sciences in Lausanne, the University Medical Center in Leiden, and Institut du Cerveau et de la Moelle Epinière in Paris. Each contributes complementary expertise to the objective of developing a cell therapy with the potential to cure type 1 diabetes.  

Cell therapy for type 1 diabetes

Type 1 diabetes can appear at any age but is the major form of diabetes diagnosed under age 40. Patients with type 1 disease can no longer produce insulin and therefore become life-long dependent on daily insulin administration. Treatment with exogenous insulin does not eliminate the risks for complications, some potentially life-threatening. The disease also has a significant impact on quality of life.  Beta cell implants prepared from human donor pancreases can restore endogenous insulin production and glucose control, but shortage of human donor organs limits implementation of this form of cell therapy.  Human pluripotent stem cells may overcome these limitations as they represent a large-scale cell source that can be differentiated into pancreatic cells in the laboratory under highly controlled conditions.

About the Center for Beta Cell Therapy in Diabetes

The Center for Beta Cell Therapy in Diabetes is a coordination core for studies and interventions that aim development of prevention and cure of type 1 diabetes.  The objective of the projects is to preserve or to replace a functional beta cell mass that can achieve long-term metabolic control in patients.  They are undertaken by an international consortium with partners from research institutions, university hospitals, and bio-industry.  Since its inception in 2002, the Center and its consortium have received support from the European Union through the FP6, FP7, and Horizon 2020 programs, from JDRF (formerly known as the Juvenile Diabetes Research Foundation) and from Flanders Innovation & Entrepreneurship.  The Center is based on the Brussels Health Campus of Vrije Universiteit Brussel. For the present program on stem cell-derived implants in diabetes, it coordinates activities by consortium partners in Brussels (UZ Brussel and VUB), San Diego (ViaCyte), Milan (San Raffaele Hospital Diabetes Research Institute), Lausanne (Nestlé Institute of Health Sciences), Leiden (the University Medical Center) and Paris (Institut du Cerveau et de la Moelle Epinière). For more information, please visit www.betacelltherapy.org

Center for Beta Cell Therapy Contact:
Brussels Health Campus Vrije Universiteit Brussel
Laarbeeklaan 103, 1090 Brussels
+32 2 477 45 40   
center@betacelltherapy.org

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two product candidates in clinical-stage development.  The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes.  The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin.  ViaCyte is also seeking to develop immune-evasive ‘universal donor’ stem cell lines in collaboration with CRISPR Therapeutics, from its proprietary CyT49 cell line, which are expected to further broaden the availability of cell therapy for diabetes and other potential indications.  ViaCyte is headquartered in San Diego, California.  ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.  For more information, please visit www.viacyte.com

ViaCyte Media Contact:
Jessica Yingling, Ph.D., Little Dog Communications, Inc.
+1-858-344-8091
jessica@litldog.com

Contact us
Gina Volkaert Responsable external communication, UZ Brussel
Gina Volkaert Responsable external communication, UZ Brussel
About UZ Brussel

UZ Brussel (University Hospital Brussels) has a staff of more than 3,800 employees. It is attached to the Faculty of Medicine and Pharmacy of the Free University of Brussels on the Brussels Health Campus in Jette. With 721 hospital beds, it accounts for 31,501 admissions of patients each year from Belgium and abroad, 396,234 consultations (emergencies not included) and 75,646 patients at the emergency care. Its philosophy is founded on three principles: Dutch-speaking, pluralist and social. As a university hospital, it also has a teaching mission and conducts scientific research. More information can be found at www.uzbrussel.be.

UZ Brussel
Laarbeeklaan 101
1090 Jette